Orlando, FL (Vocus) June 28, 2010
New research presented at the American Diabetes Association’s 70th Scientific Sessions in Orlando, Florida on June 27, 2010, suggests that a medical food developed by Metagenics, Inc. called UltraMeal® PLUS 360° enhances the cardiovascular disease (CVD) risk-lowering benefits of a Mediterranean-style low-glycemic-load diet.
A Mediterranean-style low-glycemic-load diet emphasizing “good” fats, whole grains, fresh produce, and fish, has been shown to be effective in addressing metabolic syndrome, a cluster of conditions that affects nearly a third of adults in the U.S. and increases their risk to develop cardiovascular disease, type 2 diabetes, and many other chronic diseases. Metabolic syndrome is defined as the presence of three or more of the following: elevated blood pressure, elevated blood sugar, central obesity (“apple shape”), elevated blood triglycerides, and low HDL (“good cholesterol”).
The key ingredients in UltraMeal PLUS 360° are soy protein (shown to have cholesterol-lowering effects and which may be more beneficial than animal protein in reducing the risk of heart disease); plant sterols (shown to promote healthy cholesterol levels); and hops rho iso-alpha acids and acacia proanthocyanidins (which function as selective kinase response modulators).
Recently, a team of researchers from the University of Florida College of Medicine in Jacksonville, FL compared the effects of two dietary interventions on CVD risk factors in 47 women with metabolic syndrome. In the 12-week, two-arm, randomized, parallel group study, participants received a Mediterranean-style, low-glycemic-load diet alone or in conjunction with UltraMeal PLUS 360°.
Both groups experienced improvements in the following markers of CVD risk:
- Improvements in total cholesterol, LDL-C, apolipoprotein B (apoB) and non-high density lipoprotein cholesterol (non-HDL-C) compared to baseline.
- Reduction in total LDL particle number
The group that additionally received UltraMeal PLUS 360° experienced:
- Reductions in triglycerides, apoB/apoA-1, cholesterol/HDL, and small LDL particle number
- Greater reductions in total cholesterol, LDL-C, non-HDL-C, apoB, total LDL particle number, and small LDL particle number
According to lead researcher, Mark McIntosh, MD, “All of our subjects benefited from switching to this heart-healthy diet for 12 weeks. But those who received the medical food which contained the plant sterols, hops rho iso-alpha acids and acacia proanthocyanidins experienced additional benefits. We believe this combination of healthy eating and targeted nutrients offers an effective therapeutic option for clinicians whose patients suffer from metabolic syndrome.”
The study was conducted by Dr. McIntosh, Colleen J. Kalynych, Clare Vukich, Vivek Kumar, Michelle Lott (all of the University of Florida College of Medicine/Jacksonville) and Robert Lerman (of MetaProteomics, LLC, a wholly-owned subsidiary of Metagenics, Inc.) and sponsored by Metagenics, Inc.
About MetaProteomics, LLC
MetaProteomics, LLC is focused on discovering and developing orally bioavailable, small molecule therapeutics for prevention and treatment of chronic diseases such as cardiometabolic syndrome and type 2 diabetes. MetaProteomics employs a proprietary discovery platform to identify bioactive agents, such as selective kinase response modulators (SKRMs) that can be safely used for long-term management of chronic disease. MetaProteomics is a wholly-owned subsidiary of Metagenics, Inc.
About Metagenics, Inc.
Metagenics, Inc. is a global life sciences company focused on improving health. Since 1983 Metagenics has helped health care professionals and their patients throughout the world find solutions to their most pressing health concerns with high quality, science-based medical foods, nutraceuticals, and lifestyle therapy programs.
For further information or to interview Drs. McIntosh or Lerman, contact Lisa Freeman at Lisa(at)ScottPublicRelations(dot)com, 818-610-0270.